Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 144 articles: HTML format

Single Articles

April 2024
1. BOTTONI L, Minetti A, Realini G, Pio E, et al
   NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
   Oncogene. 2024 Apr 10. doi: 10.1038/s41388-024-03025.
   PubMed     Abstract available
   
   
   
2. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
   Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
   Oncogene. 2024 Apr 5. doi: 10.1038/s41388-024-03023.
   PubMed    
   
   
   March 2024
3. RUSSO GC, Crawford AJ, Clark D, Cui J, et al
   E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
   Oncogene. 2024 Mar 20. doi: 10.1038/s41388-024-03007.
   PubMed     Abstract available
   
   
   
4. MCCLELLAN B, Wilson CN, Brenner AJ, Jolly CA, et al
   Flotillin-1 palmitoylation is essential for its stability and subsequent tumor promoting capabilities.
   Oncogene. 2024;43:1063-1074.
   PubMed     Abstract available
   
   
   February 2024
5. PRADEEP C-, Zeisel A, Kostler WJ, Lauriola M, et al
   Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.
   Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02990.
   PubMed    
   
   
   
6. YANG L, Wang M, Wang Y, Zhu Y, et al
   LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance.
   Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02972.
   PubMed     Abstract available
   
   
   
7. ZHENG XQ, Guo JP, Yang H, Kanai M, et al
   Retraction Note: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERalpha in breast cancer.
   Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02983.
   PubMed    
   
   
   
8. REID SE, Pantaleo J, Bolivar P, Bocci M, et al
   Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence.
   Oncogene. 2024 Feb 22. doi: 10.1038/s41388-024-02973.
   PubMed     Abstract available
   
   
   
9. LIANG Y, Chen B, Xu F, Long L, et al
   LncRNA PRBC induces autophagy to promote breast cancer progression through modulating PABPC1-mediated mRNA stabilization.
   Oncogene. 2024 Feb 16. doi: 10.1038/s41388-024-02971.
   PubMed     Abstract available
   
   
   
10. VENTURUTTI L, Romero LV, Urtreger AJ, Chervo MF, et al
    Correction: Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.
    Oncogene. 2024 Feb 14. doi: 10.1038/s41388-024-02961.
    PubMed    
    
    
    
11. LAGARDE CB, Kavalakatt J, Benz MC, Hawes ML, et al
    Obesity-associated epigenetic alterations and the obesity-breast cancer axis.
    Oncogene. 2024 Feb 3. doi: 10.1038/s41388-024-02954.
    PubMed     Abstract available
    
    
    
12. BARRA J, Crosbourne I, Roberge CL, Bossardi-Ramos R, et al
    DMT1-dependent endosome-mitochondria interactions regulate mitochondrial iron translocation and metastatic outgrowth.
    Oncogene. 2024;43:650-667.
    PubMed     Abstract available
    
    
    January 2024
13. GARIKAPATI K, Young IC, Hong S, Rai P, et al
    Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02951.
    PubMed     Abstract available
    
    
    
14. SONG H, Zhao Z, Ma L, Zhao W, et al
    Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p/ATG13/ULK1 feedback loop.
    Oncogene. 2024 Jan 27. doi: 10.1038/s41388-024-02950.
    PubMed     Abstract available
    
    
    
15. XU B, Sun H, Liu S, Liao L, et al
    IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion.
    Oncogene. 2024 Jan 12. doi: 10.1038/s41388-023-02934.
    PubMed     Abstract available
    
    
    December 2023
16. PENG Y, Liu X, Liu X, Cheng X, et al
    RCCD1 promotes breast carcinogenesis through regulating hypoxia-associated mitochondrial homeostasis.
    Oncogene. 2023;42:3684-3697.
    PubMed     Abstract available
    
    
    November 2023
17. LYU F, Wu K, Wu SY, Deshpande RP, et al
    Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02893.
    PubMed     Abstract available
    
    
    
18. YANG P, Yang X, Wang D, Yang H, et al
    PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERalpha.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02905.
    PubMed     Abstract available
    
    
    
19. MUSTAFA EH, Laven-Law G, Kikhtyak Z, Nguyen V, et al
    Selective inhibition of CDK9 in triple negative breast cancer.
    Oncogene. 2023 Nov 24. doi: 10.1038/s41388-023-02892.
    PubMed     Abstract available
    
    
    October 2023
20. YAO L, Hao Q, Wang M, Chen Y, et al
    KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer.
    Oncogene. 2023 Oct 16. doi: 10.1038/s41388-023-02858.
    PubMed     Abstract available
    
    
    
21. WANG Y, Liu X, Wang M, Wang Y, et al
    UBE3B promotes breast cancer progression by antagonizing HIF-2alpha degradation.
    Oncogene. 2023 Oct 2. doi: 10.1038/s41388-023-02842.
    PubMed     Abstract available
    
    
    September 2023
22. LUO Y, Zhu Q, Xiang S, Wang Q, et al
    Downregulated circPOKE promotes breast cancer metastasis through activation of the USP10-Snail axis.
    Oncogene. 2023 Sep 16. doi: 10.1038/s41388-023-02823.
    PubMed     Abstract available
    
    
    
23. LIU Z, Hou P, Fang J, Zhu J, et al
    Mesenchymal stromal cells confer breast cancer doxorubicin resistance by producing hyaluronan.
    Oncogene. 2023 Sep 14. doi: 10.1038/s41388-023-02837.
    PubMed     Abstract available
    
    
    
24. RUSSO RIC, Beguelin W, Flaque MCD, Proietti CJ, et al
    Correction: Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
    Oncogene. 2023 Sep 8. doi: 10.1038/s41388-023-02832.
    PubMed    
    
    
    
25. SAMUELS M, Jones W, Towler B, Turner C, et al
    The role of non-coding RNAs in extracellular vesicles in breast cancer and their diagnostic implications.
    Oncogene. 2023 Sep 5. doi: 10.1038/s41388-023-02827.
    PubMed     Abstract available
    
    
    July 2023
26. GUO L, Zhang W, Zhang X, Wang J, et al
    A novel transcription factor SIPA1: identification and verification in triple-negative breast cancer.
    Oncogene. 2023 Jul 27. doi: 10.1038/s41388-023-02787.
    PubMed     Abstract available
    
    
    
27. PUJALS M, Mayans C, Bellio C, Mendez O, et al
    RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer.
    Oncogene. 2023 Jul 19. doi: 10.1038/s41388-023-02778.
    PubMed     Abstract available
    
    
    
28. PAN JK, Lin WD, Kuo YL, Chen YC, et al
    ICAM2 initiates trans-blood-CSF barrier migration and stemness properties in leptomeningeal metastasis of triple-negative breast cancer.
    Oncogene. 2023 Jul 19. doi: 10.1038/s41388-023-02769.
    PubMed     Abstract available
    
    
    
29. HAN J, Qu H, Han M, Ding Y, et al
    Retraction Note: MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer.
    Oncogene. 2023 Jul 7. doi: 10.1038/s41388-023-02774.
    PubMed    
    
    
    
30. WU J, Kramer K, Crowe DL
    Lysine metabolism is a novel metabolic tumor suppressor pathway in breast cancer.
    Oncogene. 2023 Jul 1. doi: 10.1038/s41388-023-02766.
    PubMed     Abstract available
    
    
    June 2023
31. SAWANT M, Wilson A, Sridaran D, Mahajan K, et al
    Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor.
    Oncogene. 2023 Jun 17. doi: 10.1038/s41388-023-02747.
    PubMed     Abstract available
    
    
    
32. BERTOLINI I, Perego M, Ghosh JC, Kossenkov AV, et al
    Correction: NFkappaB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment.
    Oncogene. 2023 Jun 16. doi: 10.1038/s41388-023-02752.
    PubMed    
    
    
    
33. MENG D, Zhao X, Yang YC, Navickas A, et al
    A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer.
    Oncogene. 2023 Jun 1. doi: 10.1038/s41388-023-02737.
    PubMed     Abstract available
    
    
    
34. LI L, Wang X, Hu K, Liu X, et al
    ZNF133 is a potent suppressor in breast carcinogenesis through dampening L1CAM, a driver for tumor progression.
    Oncogene. 2023;42:2166-2182.
    PubMed     Abstract available
    
    
    May 2023
35. LI Y, Li L, Qin J, Wu J, et al
    Correction to: OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta1 autocrine to promote EMT and metastasis in breast cancer.
    Oncogene. 2023 May 31. doi: 10.1038/s41388-023-02736.
    PubMed    
    
    
    
36. ZHANG H, Wong CCL, Wei H, Gilkes DM, et al
    Retraction Note: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs.
    Oncogene. 2023 May 23. doi: 10.1038/s41388-023-02720.
    PubMed    
    
    
    April 2023
37. HUNT BG, Davis JC, Fox LH, Vicente-Munoz S, et al
    RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence.
    Oncogene. 2023 Apr 7. doi: 10.1038/s41388-023-02688.
    PubMed     Abstract available
    
    
    March 2023
38. BELLO ROUFAI D, Goncalves A, De La Motte Rouge T, Akla S, et al
    Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02615.
    PubMed    
    
    
    
39. ABDULLAH A, Akhand SS, Paez JSP, Brown W, et al
    Correction: Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02654.
    PubMed    
    
    
    
40. MA Y, Zhu Y, Shang L, Qiu Y, et al
    LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02652.
    PubMed     Abstract available
    
    
    
41. WU M-, Kim MR, Chen Y-, Yang J-, et al
    Correction: Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCzeta pathway.
    Oncogene. 2023 Mar 3. doi: 10.1038/s41388-023-02616.
    PubMed    
    
    
    
42. HENRIET E, Knutsdottir H, Grasset EM, Dunworth M, et al
    Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs.
    Oncogene. 2023;42:737-747.
    PubMed     Abstract available
    
    
    
43. STEBBING J, Takis PG, Sands CJ, Maslen L, et al
    Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS).
    Oncogene. 2023;42:825-832.
    PubMed     Abstract available
    
    
    February 2023
44. NAIR RS, Kumar S, Das S, Singh SK, et al
    TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer.
    Oncogene. 2023 Feb 22. doi: 10.1038/s41388-023-02633.
    PubMed     Abstract available
    
    
    
45. BAEK ML, Lee J, Pendleton KE, Berner MJ, et al
    Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
    Oncogene. 2023 Feb 22. doi: 10.1038/s41388-023-02596.
    PubMed     Abstract available
    
    
    
46. YOUSEFI H, Khosla M, Lauterboeck L, Okpechi SC, et al
    Correction to: A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
    Oncogene. 2023 Feb 9. doi: 10.1038/s41388-023-02608.
    PubMed    
    
    
    
47. BUDHRAM-MAHADEO VS, Irshad S, Bowen S, Lee SA, et al
    Correction: Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells.
    Oncogene. 2023 Feb 9. doi: 10.1038/s41388-023-02614.
    PubMed    
    
    
    
48. ACHOUR C, Bhattarai DP, Groza P, Roman AC, et al
    METTL3 regulates breast cancer-associated alternative splicing switches.
    Oncogene. 2023 Feb 1. doi: 10.1038/s41388-023-02602.
    PubMed     Abstract available
    
    
    January 2023
49. BERTOLINI I, Perego M, Ghosh JC, Kossenkov AV, et al
    Correction: NFkappaB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment.
    Oncogene. 2023 Jan 27. doi: 10.1038/s41388-023-02609.
    PubMed    
    
    
    
50. YANG X, Cruz MI, Nguyen EV, Huang C, et al
    The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer.
    Oncogene. 2023 Jan 24. doi: 10.1038/s41388-023-02594.
    PubMed     Abstract available
    
    
    
51. JIANG Y, Luo Z, Gong Y, Fu Y, et al
    NAD(+) supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling.
    Oncogene. 2023 Jan 23. doi: 10.1038/s41388-023-02592.
    PubMed     Abstract available
    
    
    
52. JAYACHANDRAN P, Battaglin F, Strelez C, Lenz A, et al
    Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.
    Oncogene. 2023 Jan 18. doi: 10.1038/s41388-022-02584.
    PubMed     Abstract available
    
    
    
53. BELLO ROUFAI D, Goncalves A, De La Motte Rouge T, Akla S, et al
    Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
    Oncogene. 2023 Jan 7. doi: 10.1038/s41388-022-02585.
    PubMed     Abstract available
    
    
    
54. CHEN F, Gurler SB, Novo D, Selli C, et al
    RAC1B function is essential for breast cancer stem cell maintenance and chemoresistance of breast tumor cells.
    Oncogene. 2023 Jan 5. doi: 10.1038/s41388-022-02574.
    PubMed     Abstract available
    
    
    
55. ZENG W, Xiong L, Wu W, Li S, et al
    CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype.
    Oncogene. 2023;42:224-237.
    PubMed     Abstract available
    
    
    
56. ZHANG Y, Song Y, Ren S, Zhang M, et al
    GPER-mediated stabilization of HIF-1alpha contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells.
    Oncogene. 2023;42:184-197.
    PubMed     Abstract available
    
    
    December 2022
57. TWAFRA S, Sokolik CG, Sneh T, Srikanth KD, et al
    Correction: A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis.
    Oncogene. 2022 Dec 9. doi: 10.1038/s41388-022-02522.
    PubMed    
    
    
    
58. LI F, Niu M, Qin K, Guo R, et al
    FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
    Oncogene. 2022 Dec 2. doi: 10.1038/s41388-022-02559.
    PubMed     Abstract available
    
    
    November 2022
59. LI C, Lee H, Jung JH, Zhang Y, et al
    Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation.
    Oncogene. 2022 Nov 17. pii: 10.1038/s41388-022-02541.
    PubMed     Abstract available
    
    
    
60. LI M, Tsavachidis S, Wang F, Bui T, et al
    Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer.
    Oncogene. 2022 Nov 7. pii: 10.1038/s41388-022-02527.
    PubMed     Abstract available
    
    
    
61. KLOUCH KZ, Stern MH, Trabelsi-Grati O, Kiavue N, et al
    Microsatellite instability detection in breast cancer using drop-off droplet digital PCR.
    Oncogene. 2022 Nov 3. pii: 10.1038/s41388-022-02504.
    PubMed     Abstract available
    
    
    
62. HU H, Zhang H, Xing Y, Zhou Y, et al
    The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.
    Oncogene. 2022 Nov 3. pii: 10.1038/s41388-022-02495.
    PubMed     Abstract available
    
    
    
63. BLAZQUEZ R, Chuang HN, Wenske B, Trigueros L, et al
    Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain.
    Oncogene. 2022;41:5008-5019.
    PubMed     Abstract available
    
    
    
64. LIN M, Ku AT, Dong J, Yue F, et al
    STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential.
    Oncogene. 2022;41:5214-5222.
    PubMed     Abstract available
    
    
    October 2022
65. UNLU B, Kocaturk B, Rondon AMR, Lewis CS, et al
    Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer.
    Oncogene. 2022 Oct 21. pii: 10.1038/s41388-022-02511.
    PubMed     Abstract available
    
    
    
66. TWAFRA S, Sokolik CG, Sneh T, Srikanth KD, et al
    A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis.
    Oncogene. 2022 Oct 18. pii: 10.1038/s41388-022-02481.
    PubMed     Abstract available
    
    
    
67. YOUSEFI H, Khosla M, Lauterboeck L, Okpechi SC, et al
    A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
    Oncogene. 2022 Oct 15. pii: 10.1038/s41388-022-02497.
    PubMed     Abstract available
    
    
    
68. DUNN S, Eberlein C, Yu J, Gris-Oliver A, et al
    AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
    Oncogene. 2022 Oct 14. pii: 10.1038/s41388-022-02482.
    PubMed     Abstract available
    
    
    
69. HARROD A, Lai CF, Goldsbrough I, Simmons GM, et al
    Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
    Oncogene. 2022 Oct 5. pii: 10.1038/s41388-022-02483.
    PubMed     Abstract available
    
    
    September 2022
70. LI Y, Deng Y, Zhao Y, Zhang W, et al
    Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02459.
    PubMed     Abstract available
    
    
    August 2022
71. VULIN M, Jehanno C, Sethi A, Correia AL, et al
    A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.
    Oncogene. 2022 Aug 25. pii: 10.1038/s41388-022-02429.
    PubMed     Abstract available
    
    
    
72. WEI L, Wang W, Yao J, Cui Z, et al
    PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation.
    Oncogene. 2022 Aug 16. pii: 10.1038/s41388-022-02431.
    PubMed     Abstract available
    
    
    
73. MORALES-VALENCIA J, Lau L, Marti-Nin T, Ozerdem U, et al
    Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression.
    Oncogene. 2022 Aug 11. pii: 10.1038/s41388-022-02433.
    PubMed     Abstract available
    
    
    
74. OH KS, Nam AR, Bang JH, Seo HR, et al
    A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers.
    Oncogene. 2022;41:3939-3952.
    PubMed     Abstract available
    
    
    
75. TARANTINO D, Walker C, Weekes D, Pemberton H, et al
    Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance.
    Oncogene. 2022;41:3969-3977.
    PubMed     Abstract available
    
    
    
76. BELLENGHI M, Talarico G, Botti L, Puglisi R, et al
    SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model.
    Oncogene. 2022;41:4055-4065.
    PubMed     Abstract available
    
    
    July 2022
77. BELL ES, Shah P, Zuela-Sopilniak N, Kim D, et al
    Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer.
    Oncogene. 2022 Jul 27. pii: 10.1038/s41388-022-02420.
    PubMed     Abstract available
    
    
    
78. GU Y, Gao H, Zhang H, John A, et al
    TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.
    Oncogene. 2022 Jul 21. pii: 10.1038/s41388-022-02415.
    PubMed     Abstract available
    
    
    
79. LIU C, Wang J, Zheng Y, Zhu Y, et al
    Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin alphavbeta3.
    Oncogene. 2022 Jul 19. pii: 10.1038/s41388-022-02409.
    PubMed     Abstract available
    
    
    
80. QUEK LE, van Geldermalsen M, Guan YF, Wahi K, et al
    Glutamine addiction promotes glucose oxidation in triple-negative breast cancer.
    Oncogene. 2022 Jul 18. pii: 10.1038/s41388-022-02408.
    PubMed     Abstract available
    
    
    June 2022
81. SHEN J, Huang Q, Jia W, Feng S, et al
    YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through enhancer in breast cancer.
    Oncogene. 2022 Jun 30. pii: 10.1038/s41388-022-02344.
    PubMed     Abstract available
    
    
    
82. BUSCHHAUS JM, Rajendran S, Humphries BA, Cutter AC, et al
    Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer.
    Oncogene. 2022 Jun 22. pii: 10.1038/s41388-022-02385.
    PubMed     Abstract available
    
    
    
83. RONG Z, Zhang L, Li Z, Xiao Z, et al
    Correction: SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling.
    Oncogene. 2022 Jun 14. pii: 10.1038/s41388-022-02374.
    PubMed    
    
    
    
84. KUMARASAMY V, Nambiar R, Wang J, Rosenheck H, et al
    RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
    Oncogene. 2022 Jun 9. pii: 10.1038/s41388-022-02362.
    PubMed     Abstract available
    
    
    
85. MEIJER TG, Nguyen L, Van Hoeck A, Sieuwerts AM, et al
    Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Oncogene. 2022;41:3498-3506.
    PubMed     Abstract available
    
    
    May 2022
86. RATZE MAK, Koorman T, Sijnesael T, Bassey-Archibong B, et al
    Correction: Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
    Oncogene. 2022 May 24. pii: 10.1038/s41388-022-02355.
    PubMed    
    
    
    
87. ZHAO Y, Sun H, Zhao Y, Liu Q, et al
    NSrp70 suppresses metastasis in triple-negative breast cancer by modulating Numb/TbetaR1/EMT axis.
    Oncogene. 2022 May 14. pii: 10.1038/s41388-022-02349.
    PubMed     Abstract available
    
    
    
88. SIMOND AM, Bui T, Zuo D, Sanguin-Gendreau V, et al
    Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.
    Oncogene. 2022 May 10. pii: 10.1038/s41388-022-02323.
    PubMed     Abstract available
    
    
    
89. KIM JY, Cho TM, Park JM, Park S, et al
    A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.
    Oncogene. 2022 May 2. pii: 10.1038/s41388-022-02269.
    PubMed     Abstract available
    
    
    
90. LIM JS, Lee KW, Ko KP, Jeong SI, et al
    XAF1 destabilizes estrogen receptor alpha through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis.
    Oncogene. 2022;41:2897-2908.
    PubMed     Abstract available
    
    
    
91. CHADET S, Allard J, Brisson L, Lopez-Charcas O, et al
    P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition.
    Oncogene. 2022;41:2920-2931.
    PubMed     Abstract available
    
    
    
92. PANG Z, Dong X, Deng H, Wang C, et al
    MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
    Oncogene. 2022;41:3064-3078.
    PubMed     Abstract available
    
    
    April 2022
93. KIM Y, Ko JY, Lee SB, Oh S, et al
    Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer.
    Oncogene. 2022 Apr 30. pii: 10.1038/s41388-022-02326.
    PubMed     Abstract available
    
    
    
94. RATZE MAK, Koorman T, Sijnesael T, Bassey-Archibong B, et al
    Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
    Oncogene. 2022 Apr 18. pii: 10.1038/s41388-022-02314.
    PubMed     Abstract available
    
    
    
95. WU S, Guo B, Zhang L, Zhu X, et al
    A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway.
    Oncogene. 2022;41:2163-2172.
    PubMed     Abstract available
    
    
    March 2022
96. BERTOLINI I, Perego M, Ghosh JC, Kossenkov AV, et al
    NFkappaB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment.
    Oncogene. 2022 Mar 30. pii: 10.1038/s41388-022-02280.
    PubMed     Abstract available
    
    
    
97. YANG YS, Jia XZ, Lu QY, Cai SL, et al
    Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
    Oncogene. 2022 Mar 29. pii: 10.1038/s41388-022-02278.
    PubMed     Abstract available
    
    
    
98. KOORMAN T, Jansen KA, Khalil A, Haughton PD, et al
    Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment.
    Oncogene. 2022 Mar 15. pii: 10.1038/s41388-022-02258.
    PubMed     Abstract available
    
    
    
99. RONG Z, Zhang L, Li Z, Xiao Z, et al
    SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling.
    Oncogene. 2022 Mar 11. pii: 10.1038/s41388-022-02259.
    PubMed     Abstract available
    
    
    
100. LIU R, Yang G, Bao M, Zhou Z, et al
     STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression.
     Oncogene. 2022 Mar 2. pii: 10.1038/s41388-022-02252.
     PubMed     Abstract available
     
     
     February 2022
101. TURDO A, Gaggianesi M, Di Franco S, Veschi V, et al
     Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.
     Oncogene. 2022 Feb 25. pii: 10.1038/s41388-022-02239.
     PubMed     Abstract available
     
     
     
102. LIU Y, Ma L, Hua F, Min Z, et al
     Correction: Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer.
     Oncogene. 2022 Feb 22. pii: 10.1038/s41388-022-02217.
     PubMed    
     
     
     
103. ZHANG Y, Dho SE, Othman K, Simpson CD, et al
     Numb exon 9 inclusion regulates Integrinbeta5 surface expression and promotes breast cancer metastasis.
     Oncogene. 2022 Feb 18. pii: 10.1038/s41388-022-02225.
     PubMed     Abstract available
     
     
     
104. SUN T, Wu Z, Wang X, Wang Y, et al
     Correction to: LNC942 promoting METTL14-mediated m 6 A methylation in breast cancer cell proliferation and progression.
     Oncogene. 2022 Feb 15. pii: 10.1038/s41388-022-02194.
     PubMed    
     
     
     
105. GUO XY, Liu TT, Zhu WJ, Liu HT, et al
     CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis.
     Oncogene. 2022 Feb 11. pii: 10.1038/s41388-022-02232.
     PubMed     Abstract available
     
     
     
106. XU LM, Zhang J, Ma Y, Yuan YJ, et al
     MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG.
     Oncogene. 2022 Feb 4. pii: 10.1038/s41388-022-02211.
     PubMed     Abstract available
     
     
     
107. MA A, Tang M, Zhang L, Wang B, et al
     Correction to: USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis.
     Oncogene. 2022 Feb 3. pii: 10.1038/s41388-022-02215.
     PubMed    
     
     
     
108. BIONDINI M, Kiepas A, El-Houjeiri L, Annis MG, et al
     HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
     Oncogene. 2022 Feb 2. pii: 10.1038/s41388-022-02206.
     PubMed     Abstract available
     
     
     January 2022
109. HOWLEY BV, Mohanty B, Dalton A, Grelet S, et al
     The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression.
     Oncogene. 2022 Jan 31. pii: 10.1038/s41388-022-02199.
     PubMed     Abstract available
     
     
     
110. ZOU H, Luo J, Guo Y, Liu Y, et al
     RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7.
     Oncogene. 2022 Jan 31. pii: 10.1038/s41388-022-02198.
     PubMed     Abstract available
     
     
     
111. MA Y, Zhang H, Chen C, Liu L, et al
     TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer.
     Oncogene. 2022 Jan 28. pii: 10.1038/s41388-022-02204.
     PubMed     Abstract available
     
     
     
112. ZIGROSSI A, Hong LK, Ekyalongo RC, Cruz-Alvarez C, et al
     SELENOF is a new tumor suppressor in breast cancer.
     Oncogene. 2022 Jan 27. pii: 10.1038/s41388-021-02158.
     PubMed     Abstract available
     
     
     
113. OKPECHI SC, Yousefi H, Nguyen K, Cheng T, et al
     Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.
     Oncogene. 2022 Jan 22. pii: 10.1038/s41388-021-02150.
     PubMed     Abstract available
     
     
     
114. AVALLE L, Raggi L, Monteleone E, Savino A, et al
     STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.
     Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02172.
     PubMed     Abstract available
     
     
     
115. LIU Y, Ma L, Hua F, Min Z, et al
     Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer.
     Oncogene. 2022 Jan 13. pii: 10.1038/s41388-021-02061.
     PubMed     Abstract available
     
     
     
116. SHU L, Chen A, Li L, Yao L, et al
     NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation.
     Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02142.
     PubMed     Abstract available
     
     
     
117. BUI T, Gu Y, Ancot F, Sanguin-Gendreau V, et al
     Emergence of beta1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment.
     Oncogene. 2022;41:527-537.
     PubMed     Abstract available
     
     
     
118. CICEK E, Circir A, Oyken M, Akbulut Caliskan O, et al
     EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers.
     Oncogene. 2022;41:220-232.
     PubMed     Abstract available
     
     
     
119. KUIKEN HJ, Dhakal S, Selfors LM, Friend CM, et al
     Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.
     Oncogene. 2022;41:112-124.
     PubMed     Abstract available
     
     
     December 2021
120. ZHANG S, Guo X, Liu X, Zhong Z, et al
     Correction to: Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation.
     Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02129.
     PubMed    
     
     
     
121. CAO X, Geradts J, Dewhirst MW, Lo HW, et al
     Correction: Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.
     Oncogene. 2021 Dec 9. pii: 10.1038/s41388-021-02043.
     PubMed    
     
     
     November 2021
122. KONG Y, Zhang Y, Wang H, Kan W, et al
     Inner nuclear membrane protein TMEM201 promotes breast cancer metastasis by positive regulating TGFbeta signaling.
     Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02098.
     PubMed     Abstract available
     
     
     
123. LI Y, Liu HT, Chen X, Wang YW, et al
     Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer.
     Oncogene. 2021 Nov 9. pii: 10.1038/s41388-021-02083.
     PubMed     Abstract available
     
     
     
124. RUIZ-TORRES SJ, Bourn JR, Benight NM, Hunt BG, et al
     Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35.
     Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02091.
     PubMed     Abstract available
     
     
     
125. YI B, Wang S, Wang X, Liu Z, et al
     CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.
     Oncogene. 2021 Nov 2. pii: 10.1038/s41388-021-02089.
     PubMed     Abstract available
     
     
     
126. ROUKENS MG, Frederiks CL, Seinstra D, Braccioli L, et al
     Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation.
     Oncogene. 2021;40:6343-6353.
     PubMed     Abstract available
     
     
     
127. BOLADO-CARRANCIO A, Lee M, Ewing A, Muir M, et al
     ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling.
     Oncogene. 2021;40:6235-6247.
     PubMed     Abstract available
     
     
     October 2021
128. TANG SC, Lion Q, Peulen O, Chariot P, et al
     The E3 ligase COP1 promotes ERalpha signaling and suppresses EMT in breast cancer.
     Oncogene. 2021 Oct 29. pii: 10.1038/s41388-021-02038.
     PubMed     Abstract available
     
     
     
129. CHERADAME L, Guerrera IC, Gaston J, Schmitt A, et al
     STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.
     Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-02037.
     PubMed     Abstract available
     
     
     
130. BLOCK CJ, Mitchell AV, Wu L, Glassbrook J, et al
     RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
     Oncogene. 2021 Oct 4. pii: 10.1038/s41388-021-02030.
     PubMed     Abstract available
     
     
     September 2021
131. PALMA FR, Ratti BA, Paviani V, Coelho DR, et al
     AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism.
     Oncogene. 2021;40:5455-5467.
     PubMed     Abstract available
     
     
     August 2021
132. MAJHI PD, Griner NB, Mayfield JA, Compton S, et al
     Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome.
     Oncogene. 2021;40:5026-5037.
     PubMed     Abstract available
     
     
     July 2021
133. ZHANG J, Liu Y, Tan J, Zhang Y, et al
     Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC.
     Oncogene. 2021;40:4783-4795.
     PubMed     Abstract available
     
     
     
134. ZHAO Z, Guo Y, Liu Y, Sun L, et al
     Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer.
     Oncogene. 2021;40:4604-4614.
     PubMed     Abstract available
     
     
     
135. LIU X, Li L, Si F, Huang L, et al
     NK and NKT cells have distinct properties and functions in cancer.
     Oncogene. 2021;40:4521-4537.
     PubMed     Abstract available
     
     
     June 2021
136. PROKAKIS E, Dyas A, Grun R, Fritzsche S, et al
     USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
     Oncogene. 2021;40:4004-4018.
     PubMed     Abstract available
     
     
     April 2021
137. MAI J, Peng XD, Tang J, Du T, et al
     AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation.
     Oncogene. 2021;40:2422-2436.
     PubMed     Abstract available
     
     
     
138. MARTINEZ-ORDONEZ A, Seoane S, Avila L, Eiro N, et al
     POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation.
     Oncogene. 2021;40:2725-2740.
     PubMed     Abstract available
     
     
     
139. CHEN T, Wang X, Li C, Zhang H, et al
     CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.
     Oncogene. 2021;40:2756-2771.
     PubMed     Abstract available
     
     
     
140. KIM H, Son S, Ko Y, Shin I, et al
     CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer.
     Oncogene. 2021;40:2667-2681.
     PubMed     Abstract available
     
     
     
141. BERDIEL-ACER M, Maia A, Hristova Z, Borgoni S, et al
     Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.
     Oncogene. 2021;40:2651-2666.
     PubMed     Abstract available
     
     
     March 2021
142. AHMED SF, Buetow L, Gabrielsen M, Lilla S, et al
     E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
     Oncogene. 2021;40:2149-2164.
     PubMed     Abstract available
     
     
     
143. LIN CC, Yang WH, Lin YT, Tang X, et al
     DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
     Oncogene. 2021;40:2018-2034.
     PubMed     Abstract available
     
     
     
144. YE Z, Wang D, Lu Y, He Y, et al
     Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZbeta.
     Oncogene. 2021;40:1775-1791.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.